Development of potent and selective tissue transglutaminase inhibitors: their effect on TG2 function and application in pathological conditions

Research output: Contribution to journalArticle

View graph of relations Save citation

Open

Authors

Research units

Abstract

Potent-selective peptidomimetic inhibitors of tissue transglutaminase (TG2) were developed through a combination of protein-ligand docking and molecular dynamic techniques. Derivatives of these inhibitors were made with the aim of specific TG2 targeting to the intra- and extracellular space. A cell-permeable fluorescently labeled derivative enabled detection of in situ cellular TG2 activity in human umbilical cord endothelial cells and TG2-transduced NIH3T3 cells, which could be enhanced by treatment of cells with ionomycin. Reaction of TG2 with this fluorescent inhibitor in NIH3T3 cells resulted in loss of binding of TG2 to cell surface syndecan-4 and inhibition of translocation of the enzyme into the extracellular matrix, with a parallel reduction in fibronectin deposition. In human umbilical cord endothelial cells, this same fluorescent inhibitor also demonstrated a reduction in fibronectin deposition, cell motility, and cord formation in Matrigel. Use of the same inhibitor in a mouse model of hypertensive nephrosclerosis showed over a 40% reduction in collagen deposition.

Documents

Details

Original languageEnglish
Pages (from-to)1347-1361
Number of pages15
JournalChemistry and Biology
Volume22
Issue number10
Early online date9 Oct 2015
DOIs
Publication statusPublished - 22 Oct 2015

Bibliographic note

© 2015, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ Cell Press papers are freely available starting 12 months after publication. Supplementary Information: http://dx.doi.org/10.1016/j.chembiol.2015.08.013

    Keywords

  • irreversible tissue transglutaminase inhibitors

Download statistics

No data available

Employable Graduates; Exploitable Research

Copy the text from this field...